AstraZeneca logo

Cardiovascular Disease and Type 2 Diabetes: Defining the Therapeutic Crossroads for Primary and Secondary Prevention

Date: April 22, 3:00 pm ET

Part of our Clinical Conversations Webinar Series! Connect the dots between T2D, CVD, and CVD risk factors. Plus, learn to define primary and secondary prevention of CVD; apply current management strategies for comorbidities in patients with T2D; and explain primary and secondary cardiovascular prevention in patients with type 2 diabetes.



Click on a name to learn more about the speaker.

Brought to you in partnership with